Sutro Biopharma STRO Change in Deferred Revenue
Change in Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's change in deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's change in deferred revenue?
- Sutro Biopharma (STRO) reported change in deferred revenue of -$1.96M in Q1 2026.
- How has Sutro Biopharma's change in deferred revenue changed year-over-year?
- Sutro Biopharma's change in deferred revenue increased by 59.0% year-over-year, from -$4.78M to -$1.96M.
- What is the long-term trend for Sutro Biopharma's change in deferred revenue?
- Over 2 years (2021 to 2025), Sutro Biopharma's change in deferred revenue has grown at a 114.1% compound annual growth rate (CAGR), from -$15.21M to -$69.73M.
- What does change in deferred revenue mean?
- Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.